Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. حسب Chen Lu (135200)

الموضوعات:

Utilization of anticoagulants at eight hospitals from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

The ANCOVA and Post_hoc results. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

The demographical and clinical characteristics of subjects at baseline. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Identification of BM-MSCs. حسب Chen Lu (135200)

الموضوعات:

CONSORT flowchart. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Effect of BM-MSCs in improving DCS induced lung injury. حسب Chen Lu (135200)

الموضوعات:

Inpatient utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

Indications for warfarin prescription in outpatients and inpatients in 2023. حسب Wei Luo (80175)

الموضوعات:

Time to stabilization in the mediolateral direction. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Outpatient utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

Participant’s data including characteristics and primary outcome measurement. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Effects of BM-MSCs on different types of lung cell death in different group. حسب Chen Lu (135200)

الموضوعات:

Time to stabilization in the vertical direction. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

DDC for four anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

A schematic representation of how BM-MSCs reduce inflammation, oxidative stress, and cell death to alleviate decompression induced acute lung injury. حسب Chen Lu (135200)

الموضوعات:

Raw Data. حسب Chen Lu (135200)

الموضوعات:

Utilization of anticoagulants from 2019 to 2023. حسب Wei Luo (80175)

الموضوعات:

The description of games. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

The expenditure on anticoagulants in the period of 2019-2023(million CNY). حسب Wei Luo (80175)

الموضوعات: